经导管三尖瓣置换术的真实世界结局:STS/ACC TVT注册分析
本研究基于STS/ACC TVT注册,回顾性纳入2024年2月至2025年3月美国82中心1034例接受经导管三尖瓣置换术的重度三尖瓣反流患者,器械成功植入率98.4%,30天全因死亡3.1%、卒中0.2%、出血7.9%,NYHA分级与KCCQ-OS评分显著改善。
要点
- 真实世界中TTVR器械植入成功率98.4%,术后及30天轻度及以下反流达98.4%与97.7%。
- 30天全因死亡3.1%、卒中0.2%、心衰住院3.1%,新CIED植入在CIED初治患者中为15.9%。
- 30天NYHA I/II级达82.7%,KCCQ-OS评分平均改善22.4分,均具统计学意义。
核心结论
- 美国TTVR早期真实世界经验证实对重度三尖瓣反流患者安全有效,30天结局与TRISCEND II关键试验一致。
研究设计与样本
- 回顾性队列研究,纳入2024年2月至2025年3月美国82中心所有连续接受TTVR的患者共1034例尝试手术。
- 患者为优化药物治疗后仍有症状性重度三尖瓣反流且经心脏团队评估适合TTVR者。
- 平均(SD)年龄77.1(10.6)岁,女性占69.1%,NYHA III/IV级占73.2%。
主要发现
- 1034例尝试手术中1017例(98.4%)成功植入瓣膜。
- 术后轻度及以下三尖瓣反流达98.4%,30天时为97.7%。
- 30天全因死亡3.1%、卒中0.2%、出血7.9%、心衰住院3.1%。
- CIED初治患者30天新CIED植入率为15.9%。
- 30天NYHA I/II级达82.7%(P < .001),KCCQ-OS评分平均改善22.4分(P < .001)。
关键数值与推荐
- 按基线CIED状态分层,30天死亡(P = .47)、心衰住院(P > .99)和功能结局(P = .55)均无显著差异。
临床怎么用
- TTVR可作为优化药物治疗后仍有症状性重度三尖瓣反流且心脏团队评估合适患者的治疗选择。
- 术后30天内需关注出血及新CIED植入风险,并评估心功能与生活质量改善。
局限性
- 为回顾性注册研究,仅报告30天结局,缺乏长期随访数据。
- 新CIED植入率与出血率低于随机临床试验经验,可能存在选择偏倚或监测差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Transcatheter tricuspid valve replacement (TTVR) demonstrated superior outcomes over medical therapy in patients with severe tricuspid regurgitation (TR) in the Edwards EVOQUE Transcatheter Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety and Clinical Efficacy Using a Novel Device II (TRISCEND II) randomized clinical trial, and received regulatory approval in the US in 2024. Contemporary real-world data on its effectiveness and safety remain limited. OBJECTIVE: To evaluate 30-day clinical, echocardiographic, and health status outcomes of TTVR in real-world use. DESIGN, SETTING, AND POPULATION: Retrospective cohort study of all consecutive patients who underwent TTVR in the US from February 2024 through March 2025 in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. Patients had symptomatic, severe TR despite optimal medical therapy and TTVR was deemed appropriate by a heart team. Statistical analysis was conducted from September 2025 to February 2026. EXPOSURE: Device-enabled TTVR. MAIN OUTCOMES AND MEASURES: Thirty-day event rates (all-cause death, stroke, bleeding, new cardiac implantable electronic device [CIED] implantation, heart failure hospitalizations), TR reduction, and changes in health status (New York Heart Association [NYHA] functional class and Kansas City Cardiomyopathy Questionnaire Overall Summary [KCCQ-OS] score) are reported. Subgroup analyses examined the impact of baseline CIED status on outcomes. RESULTS: Among 1034 attempted procedures at 82 centers (mean [SD] age, 77.1 [10.6] years; 69.1% female; 73.2% NYHA functional class III/IV), a valve was successfully implanted in 1017 patients (98.4%). Mild or less TR was achieved in 98.4% of patients post procedure and in 97.7% at 30 days. At 30 days, all-cause mortality was 3.1%; stroke, 0.2%; bleeding, 7.9%; new CIED, 15.9% in CIED-naive patients; and heart failure hospitalization, 3.1%. There were significant improvements in NYHA functional class (class I/II, 82.7%; P < .001) and mean KCCQ-OS score (22.4 points; P < .001) from baseline to 30 days. There were no significant differences in 30-day mortality (P = .47), heart failure hospitalization (P > .99), and functional outcomes (P = .55) when patients were stratified by baseline CIED status. CONCLUSIONS AND RELEVANCE: Early US real-world experience with TTVR confirms safety and effectiveness in patients with severe TR. Thirty-day outcomes are consistent with the TRISCEND II pivotal trial, demonstrating acceptable safety, near-complete TR elimination, and significant health status improvements in an older, comorbid population. Rates of new CIED implantation and bleeding were lower than randomized clinical trial experience.
引用
- Makkar RR, Gupta A, O'Neill BP, et al. Real-World Outcomes of Transcatheter Tricuspid Valve Replacement: Analysis From the STS/ACC TVT Registry. JAMA. 2026. PMID: 41973411. doi:10.1001/jama.2026.3446
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。